SPLASH Beverage Group Announces Veterinary Collaboration on CannEpil

What Happened

• On August 5, 2026, SPLASH BEVERAGE GROUP, INC. (SBEV) announced it entered a Collaboration Agreement with Lupvindol Biosciences Ltd. to develop and advance CannEpil® for veterinary uses. The announcement was made via a press release furnished as Exhibit 99.1 in the Form 8-K filed under Item 7.01 (Regulation FD Disclosure).

Key Details

• Parties: SPLASH BEVERAGE GROUP, INC. and Lupvindol Biosciences Ltd.
• Subject: Collaboration to develop and advance CannEpil® for veterinary applications.
• Filing/date: Form 8-K filed August 5, 2026; press release attached as Exhibit 99.1.
• The Form 8-K discloses the announcement but does not include financial terms or additional deal specifics in the filing.

Why It Matters

• This filing indicates SPLASH is expanding CannEpil’s potential market into veterinary medicine through a formal collaboration, showing ongoing product development activity. Investors should note the absence of disclosed financial terms or timelines in the 8-K and review the referenced press release and future filings for details on clinical plans, commercialization steps, or financial impact.